ProCE Banner Activity

CME

Advances in CAR-T Cell Therapy Across Hematologic Malignancies: From Pipeline to Clinical Practice

Multimedia
In this on-demand webcast of a live satellite symposium, expert faculty review the latest safety and efficacy data on CAR T-cell–based therapies for leukemias, lymphomas, and myeloma.

Physicians: Maximum of 2.25 AMA PRA Category 1 Credits

Released: January 13, 2022

Expiration: January 12, 2023

No longer available for credit.

Share

Faculty

Jesus G. Berdeja

Jesus G. Berdeja, MD

Director, Multiple Myeloma Program
Sarah Cannon Research Institute
Attending Physician
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Michael R. Bishop

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Jae H. Park

Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate into practice up-to-date efficacy and safety data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Discuss considerations associated with CAR T-cell therapy, including patient selection, referring patients to specialized centers, and the importance of collecting patient-reported outcomes
  • Appraise ongoing clinical trials evaluating CAR T-cell therapy for the treatment of patients with hematologic malignancies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD, has disclosed that he has received consulting fees and funds for research support from Arcellx, Autolus, Bristol-Myers Squibb, CRISPR, Kite/Gilead Sciences, and Novartis and fees for non-CME/CE services from Bristol-Myers Squibb and Kite/Gilead Sciences.

Faculty Disclosure

Primary Author

Jesus G. Berdeja, MD

Director, Multiple Myeloma Program
Sarah Cannon Research Institute
Attending Physician
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Jesús G. Berdeja, MD, has disclosed that he has received consulting fees from Bluebird Bio, Bristol-Myers Squibb, Celgene, CRISPR, Janssen, Kite, Legend, SecuraBio, and Takeda and funds for research support (to his institution) from AbbVie, Acetylon, Amgen, Astex, Bluebird Bio, Bristol-Myers Squibb, Celator, Celgene, Celularity, CRISPR, CURIS, EMD Serono, Genentech, GlaxoSmithKline, Ichnos, Incyte, Janssen, Juno, Kesios, Lilly, Millennium, Novartis, Onyx, Pharmacyclics, Poseida, Sanofi, Takeda, and Vivolux.

Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Jae H. Park, MD, has disclosed that he has received consulting fees from Allogene, Amgen, AstraZeneca, Autolus, GlaxoSmithKline, Kite, Novartis, and Takeda.

Staff Disclosure

Staff

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 13, 2022, through January 12, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.